Results 191 to 200 of about 6,899,630 (383)
Assessing Corporate Social Performance from a Contingency Theory Perspective
Mariana Cristina Ganescu
openalex +1 more source
Abstract The middle Permian represents a critical interval in therapsid evolution, when gorgonopsians emerged as some of the first specialized apex predators within terrestrial ecosystems. Despite their significance, the early diversification of Gorgonopsia in Gondwana remains poorly understood due to scarcity and fragmentary material.
Zanildo Macungo +5 more
wiley +1 more source
Transforming the Indian Private Sector for Universal Health Coverage. [PDF]
Mor N.
europepmc +1 more source
(1) Kbhb modification of FBP1 and PCK1 is involved in regulation of the gluconeogenesis pathway. (2) Kbhb of FBP1 and PCK1 is catalyzed by p300 and removed by HDACs. (3) BHB induced an increase in the enzymatic activity of FBP1 and PCK1 through Kbhb modification at the K43 site of FBP1 and the K191 site of PCK1.
DingPing Feng +6 more
wiley +1 more source
Contingent Parental Metamorphosis: A Grounded Theory of Parental Adaptation with Offspring-Affected Neurodevelopmental Disorders. [PDF]
Talebian F +3 more
europepmc +1 more source
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate to severe systemic lupus erythematosus (SLE) activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly
Susan Manzi +12 more
wiley +1 more source
Situational And Contingency Theories Of Leadership: Are They The Same
Iosr Journals, Dr Otaroghene Peretomode
openalex +1 more source
Objective Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE) and is partially driven by type I interferon signaling. Anifrolumab, an approved treatment for patients with SLE, has been investigated in a phase 2 trial in patients with LN receiving standard therapy (TULIP‐LN, ClinicalTrials.gov identifier ...
Andrea Fava +8 more
wiley +1 more source

